reviral company logo

ReViral drug discovery for RSV 

ReViral is a UK-based biotechnology company developing first in class drugs to treat RSV infections.

  • ReViral is developing a fusion inhibitor of RSV which is a highly potent, novel small molecule
  • Fusion inhibitor is a highly potent small molecule
  • ReVirals most advanced programme is in phase 1 clinical trials
  • ReVirals pipeline also includes inhibitors of RSV replication

 

Upcoming Events

June 19–22, 2017
BIO International Convention
San Diego 

Nov 6-8, 2017
BioEurope
Berlin

Jan 8-10, 2018
Biotech Showcase
San Francisco

Latest News
Apr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers
Phase 2a RSV Challenge Study Planned for Q3 2017 London, UK,...
Mar 9, 2017
Ian Dukes joins the ReViral Board
London, UK, 9th March 2017  - ReViral are proud to announce that Ian Dukes has...